NCT03931291 2025-03-17
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
Phase 2 Completed
Clinical Trials
4 trialsNCT04419389 2025-03-17
R/R
Aprea Therapeutics
Phase 1/2 Terminated
NCT03072043 2022-01-24
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00900614 2019-07-31
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Aprea Therapeutics
Phase 1 Completed